What changed in Johnson & Johnson's latest annual report
In the year ended 28 Dec 2025, Johnson & Johnson's revenue rose 6% to USD 94.19bn, from USD 88.82bn; net income rose 90.6% to USD 26.80bn, from USD 14.07bn; long-term debt rose 28.7% to USD 39.44bn, from USD 30.65bn.
Year ended 28 Dec 2025. Source: 10-K filed 11 Feb 2026, read it on SEC EDGAR.
USD 88.82bn to USD 94.19bn
The figures, year on year
| Item | Year before | Latest year | Change |
|---|---|---|---|
| Revenue | 88.82bn | 94.19bn | Up 6% |
| Net income | 14.07bn | 26.80bn | Up 90.6% |
| Total assets | 180.10bn | 199.21bn | Up 10.6% |
| Total liabilities | 108.61bn | 117.67bn | Up 8.3% |
| Long-term debt | 30.65bn | 39.44bn | Up 28.7% |
| Cash and cash equivalents | 24.11bn | 19.71bn | Down 18.2% |
Questions people ask
Did Johnson & Johnson's revenue grow last year?
Revenue grew 6%, from USD 88.82bn to USD 94.19bn in the year ended 28 Dec 2025.
Is Johnson & Johnson profitable?
Yes. Net income was USD 26.80bn in the year ended 28 Dec 2025. The year before: USD 14.07bn.
How much cash and debt does Johnson & Johnson have?
At its latest year end (28 Dec 2025), Johnson & Johnson reported cash and cash equivalents of USD 19.71bn and long-term debt of USD 39.44bn.
Where do these numbers come from?
From Johnson & Johnson's own annual filings with the SEC. Each change is calculated from the reported figures; nothing is estimated.
Meeting a client who works with Johnson & Johnson?
LYNORIQ remembers every client meeting the way this page tracks a filing: what changed since last time, what you promised, and what they owe you.
Start free See the demoOther Pharmaceutical Preparations companies
- Eli Lilly And CompanyCash and cash equivalents up 122.4%
- AbbVie Inc.Revenue up 8.6%
- Merck & Co., Inc.Long-term debt up 35.7%
- Abbott LaboratoriesNet income down 51.3%
- Pfizer IncCash and cash equivalents up 9.5%
- Vertex Pharmaceuticals Inc / MaTotal liabilities up 13.9%
- Bristol-Myers Squibb CompanyShareholders' equity up 13.1%
- Regeneron Pharmaceuticals, Inc.Cash and cash equivalents up 25.3%